Understanding Hyaluronic Acid (HA) Dermal Fillers

Understanding Hyaluronic Acid (HA) Dermal Fillers

Dermal fillers—also known as soft tissue implants, injectable gels, or wrinkle fillers—are medical devices formulated to effectively soften the appearance of wrinkles and lines. These implants can also be used to treat other frequently reported aesthetic imperfections, such as undefined facial contours, sunken facial regions, scars, dehydration, and dullness. Besides that, some fillers are also designed to non-surgically augment less than desirable facial features, like thin and shapeless lips and crooked noses. Despite the popularity of dermal fillers in the field of aesthetic medicine, a 2013 report by the Department of Health (DOH) found that there is still a lack of regulation on the usage of these devices. In fact, dermal fillers are classified as devices instead of drugs in the United Kingdom and can be used for cosmetic purposes without being regulated by the European Commission (CE), EU General Product Safety Directive, and Care Quality Commission (CQC). Most healthcare practitioners then tend to refer to the guidelines set by the U.S. Food and Drug Administration (FDA). Unfortunately, the FDA has only approved the use of 16 hyaluronic acid (HA)-based implants. Hence, they had to resort to their clinical expertise and judgement instead of relying on the guidelines set by FDA.  

Dermal filler rheology

Rheology is the in-depth study of the physical characteristics of a material and the way it behaves when it is acted upon by deforming forces. Dermal fillers are also subjected to various forces (e.g. gravity, compression, shearing, vertical compression, and stretch from muscle movements, etc.) once they are administered into the skin. The following are the four major factors that influence the physical features of HA fillers:

  • Cohesivity: The cohesiveness of a filler is directly proportional to the concentration of HA molecules and the degree of the cross-linking force that holds the HA molecules together. A dermal filler with high cohesivity can maintain its vertical projection better than fillers with lower cohesivity.
  • Elastic modulus (G’): This factor refers to the ability of a soft tissue implant to return to its original shape after undergoing shear deformation.
  • Viscous modulus (G’’): This factor refers to the inability of a soft tissue implant to return to its original shape after undergoing shear deformation.
  • Complex modulus (G*): It is the sum of the elastic modulus (G’) and viscous modulus (G’’) and refers to the total ability of a dermal filler to resist deformation.

It is imperative that aestheticians equip themselves with the rheology knowledge of dermal fillers, such as the mechanism of action of the implants and the different ways the implants behave when used in different facial regions. This will then allow the physicians to select the most suitable dermal fillers for their patients and subsequently deliver the desired aesthetic results. For example, physicians are recommended to choose a volumizing filler with low tissue spreading ability when treating the deep subdermal layers of the cheeks. On the other hand, the filler that is chosen to treat the superficial dermal layers must be able to spread easily through the tight connective tissues in the upper layers of the skin for the best outcomes. Detailed rheological properties of dermal fillers according to the treatment areas are as follows:

  • Fine Lines and Lips: The non-bulky fillers must be easily molded with high spreading ability in order to restore volume in intradermal and sub-dermal planes. Most lip and fine line plumping fillers, such as Belotero Balance, Juvederm Volbella, and Restylane Kysse, are of low viscosity, low-to-medium elasticity, and low cohesivity.
  • Nose and Chin: The implants used to correct the shape and structure of the nose and chin should only have minimal lateral spreading ability and maximum vertical projection. Suitable implants for these facial areas, such as Juvederm Voluma, Restylane Lyft, and Teosyal Ultimate, are of low viscosity, high elasticity, and high cohesivity.
  • Mid-Face: The soft tissue implants that are indicated for augmenting the mid-face region should be able to withstand compression and shear deformation. They must also be able to retain the molded shape without getting displaced from the original injection sites. Some examples of suitable fillers for this area are Restylane Lyft, Teosyal Ultimate, and Teosyal Ultra Deep. These fillers are considered suitable due to their rheological properties of low viscosity, high elasticity, and medium-to-high cohesivity. Once injected, the fillers will not only volumize the deep dermal or subdermal layer of the skin, but they will also achieve the desired projection.
  • Lower Face: The aesthetic fillers that are used to correct the lower face region must be easily malleable and non-palpable and creates minimal projection once administered into the skin. This is to ensure adequate volume restoration in the deep dermal or subdermal planes. Examples of dermal implants suitable for the lower face region are Belotero Intense, Juvederm Volift, and Teosyal Global Action, which have the rheological properties of low viscosity, moderate elasticity, and low-to-medium cohesivity.

Complications of dermal filler injections

The administration of dermal fillers is not without any health risks. Besides the usual inflammatory reactions, such as bruising, redness, and swelling, that are associated with the minimally-invasive injection process, there are other side effects that the patients should be made aware of. Infections, though an uncommon secondary effect of aesthetic filler implantation, can still happen due to viruses, bacteria, fungi, or even biofilm. [21, 22] Pathogens can camouflage themselves within a biofilm and avoid detection by the immune system and antibiotics. [22] These pathogens can then lead to other serious side effects, such as nodules, granulomatous inflammation, abscesses, and recurrent infections. Since biofilms are resistant to the actions of antibiotics, patients may need to undergo surgical debridement or excision to remove the foreign materials. The formation of nodules or granulomatous inflammation usually happens due to an abnormal tissue reaction. The latter is a type 4 hypersensitivity reaction that is mediated by T-cell or macrophage interaction. [23] Patients displaying this reaction may require triamcinolone acetonide injections, cortisone injections, or topical application of 5-florouracil. [22] Severe cases may need to be treated via surgical excision. Besides that, anaphylactic reactions, though rare, are still possible. They must be treated immediately to avoid other life-threatening health complications. The injectors must be highly skilled, trained with the latest anaphylaxis management method(s), and have the anaphylaxis equipment well-stocked so that they can administer life-saving medications accurately if the need ever arises. Dermal filler that is accidentally injected into the blood vessels can cause arterial embolization (AE) and dangerous disruption of the blood flow, resulting in pain, mottling, blanching, tissue necrosis, and ulceration. Embolization of filler material is extremely risky, as it can lead to complications like blindness, stroke, and extensive necrosis. [24] Some of the strategies that can be followed to reduce the risk of intravascular injection are as follows[25]:

  • Physicians should aspirate the needle or cannula prior to injection, even if they are pre-filled with filler gel. A blood flashback confirms that the needle tip is located within a blood vessel and consequently must be repositioned.
  • Physicians are advised to use a large diameter cannula instead of a fine gauge needle. This is because a blunt-tip cannula with a wide diameter has a lower risk of penetrating into the blood vessels and can aspirate better for a blood flashback.
  • Physicians are recommended to inject small aliquots of implant material into one area. Intravascular injection of a large volume of filler will only result in devastating results.
  • The fillers must also be administered slowly to reduce pressure damage and the risk of accidental intravascular injection.
  • It is safer to administer the filler material via retrograde injection than anterograde injection due to the former’s lower risk of intravascular injection.

Pre-procedural considerations

Prior to conducting the aesthetic procedure, there are some important factors that must be considered by both physicians and patients alike. While most of the dermal fillers are considered safe, it is important that patients’ medical histories are thoroughly reviewed. Patients with health conditions like known allergies to the filler material and/or its components, like lidocaine, and active infections are contraindicated from receiving dermal filler injections. Physical (e.g. diabetes, immunosuppression, autoimmune disease, dermatological issues, etc.) and psychological factors (e.g. anxiety, depression, body dysmorphia, etc.) that may influence the treatment session and the recovery process must be identified and managed accordingly.

Hyaluronic acid (HA)-based fillers

Hyaluronic acid is a glycosaminoglycan (GAG) polymer that is naturally abundant in the extracellular matrix of the body. The polymer is made of repeated disaccharide units of glucuronic acid and N-acetylglucosamine, and the length of the HA polymers varies extensively. The varying molecular weight of the HA polymers determines the different biological functions in the tissues. For instance, polymers with high molecular mass help to curb tissue inflammation and angiogenesis, while polymers with low molecular mass work against the high molecular polymers by increasing inflammation and angiogenesis. About half of the body’s total HA is found in the skin, with one third of that amount synthesized daily due to rapid tissue metabolism. It is one of the integral dermal cells and acts as the framework for the extracellular matrix. Not only does it provide rigidity, turgor, and adequate hydration, HA molecule also permits cellular growth and movement. Besides that, HA molecules also shield the skin from free radicals, such as UVA and UVB rays. The levels of HA in the body is carefully balanced by the enzymes that create it (e.g. synthase HAS1, HAS2, and HAS3) and those that disintegrate it (e.g. hyaluronidases HYAL1, HYAL2, and HYAL3). Nowadays, hyaluronidase is harvested synthetically to be used in enhancing the absorption and penetration of various injectable solutions, including local anesthetic agents, infusions, and subcutaneous or intramuscular injections. It can also be used to reduce swelling. That being said, hyaluronidase has also been used to prematurely dissolve HA-based fillers that deliver undesirable results. Though hyaluronidase enzymes originate from various sources, such as mammalian sources (endo-Beta- N-acetylhexosaminidase), microbial sources (Hyaluronate lyase), and leech/hookworm sources (endo-Beta-D-glucuronidase), the most commonly used preparation of hyaluronidase in the UK is Hyalase, which is made from sheep testes. That being said, microbial- and human-based hyaluronidases still deliver efficient results since they have superior safety profiles and reduced risks of immunogenic reactions.

Hyaluronic acid-based dermal fillers are made of long chains of HA polymers that are stabilized and cross-linked with each other through chemical reticulating agents, such as 1,4-butanediol diglycidyl ether (BDDE) for Belotero, Juvederm, and Restylane; 1,2,7,8-diepoxyoctane (DEO) for Puragen; and divinyl sulfone (DVX) for Hylaform. The resulting filler material is then reconstituted into a phosphate-buffered solution and processed into a homogenous gel or a suspension of HA molecules in a gel carrier. Thanks to the variability in manufacturing processes, the HA fillers are differentiated based on their particle size, strength, and degree of cross-linking; in turn, these properties determine the effectiveness of the fillers. On the other hand, there are stable complexes of HA that are cross-linked using hydrogen bonds. These fillers are considered safer than the fillers cross-linked with chemical reticulating agents, as they pose less of a risk for causing allergic reactions. Hence, these implants tend to be better tolerated by patients with sensitive immune systems.

Hyaluronic acid-based injectable fillers can be classified based on their gel textures, which are either monophasic or biphasic. Monophasic fillers are made of a single phase of HA molecules; they can be monodensified (e.g. Juvederm and Teosyal) or polydensified (e.g. Belotero) depending on the stages of cross-linking. On the other hand, biphasic implants, such as Restylane and Perlane, are made of two phases of HA, with the cross-linked HA molecules suspended uniformly and a non-crosslinked HA acting as the carrier gel. There is no single type of HA filler that is superior to the others; physicians are recommended to choose a filler that is most suitable to their patients’ aesthetic indications, treatment areas, underlying medical conditions, and budgets.

Non-hyaluronic acid fillers

Besides HA, dermal fillers are also made of the following materials:

  • Collagen: Collagen can be extracted from sources such as bovine, porcine, and even human donors. Just like HA fillers, collagen implants are used to treat many aesthetic issues. For example, superficial injections of collagen fillers can help to soften the appearance of scars and wrinkles, while deep dermal injections can help to correct deep-set creases and facial contours. They can also be mixed with polymethylmethacrylate (PMMA) or other gel carriers for enhanced aesthetic improvements.
  • Polymethylmethacrylate (PMMA): Polymethylmethacrylate (PMMA) is actually a polymer of acrylic. PMMA-based fillers exist as non-absorbable microspheres that will encourage the fibroblasts to encapsulate each PMMA microparticle, synthesize newer collagen fibers via neocollagenesis, and increase tissue volume via fibroplasia. An example of a PMMA filler is Artefill, which is the only PMMA-based filler that is approved by the FDA for use in correcting acne scars and nasolabial folds. It is made of PMMA microbeads that are uniformly suspended in bovine collagen. However, the original version of Artefill was infamous for its high rate (up to 2.5%) of post-injection granulomas. Patients must undergo skin testing prior to receiving Artefill injections to reduce the risk of allergic reactions associated with the bovine collagen. Compared to HA-based fillers that only offer non-permanent results, Artefill delivers permanent aesthetic enhancements, so they require surgical removal should there be any health complications or need for correction.
  • Calcium Hydroxylapatite (CaHA): Calcium hydroxylapatite is a completely synthetic compound that shares a similar structure to the bones and teeth. As of now, Radiesse is the only CaHA-based filler that is approved for use by the FDA. 30% of the product consists of CaHA microspheres that are suspended in an aqueous gel carrier, which makes up the remaining 70% of the product. Since it is synthetic and non-immunogenic, patients do not need to undergo skin patch tests. Once injected, the filler is able to correct aesthetic issues like moderate wrinkles and skin folds, with the corrective results lasting for about a year. Radiesse can also be used to correct facial lipoatrophy in patients with advanced Human Immunodeficiency Virus (HIV) infections.
  • Poly-L-lactic Acid (PLLA): Just like PMMA fillers, PLLA implants are made of absorbable polymers that encourage the fibroblasts to regenerate healthier and stronger collagen fibers. Physicians are advised to give multiple injections of PLLA fillers for optimal outcomes, which should last for about 2 years. However, the administration of a PLLA implant may result in the delayed formation of palpable nodules. That being said, a five-year prospective research study conducted by Woerle et al. among 300 patients demonstrated that the incidence of nodule formation is well below 1% if the filler is injected with the proper handling of the vials, adequate dilution, a longer hydration time, and the addition of lidocaine. As of yet, Sculptra is the only FDA-approved PLLA-based implant that can be used for the treatment of facial lipoatrophy in HIV patients.

Besides the types of fillers listed above, there are also other less common types of dermal fillers, such as dextran particles, autologous fat transfer, polycaprolactone, agarose gel, and polyacrylamide gel.


As stated earlier, HA is a naturally-occurring molecule that helps to maintain the health and functionality of skin. Hyaluronic acid molecules that are harvested for cosmetic purposes must be reticulated and stabilized with chemical cross-linking agents, such as 1,4-butanediol diglycidyl ether (BDDE). This important step allows the HA fillers to resist premature degradation and provide durable aesthetic results once they are injected into the problematic areas. Due to vast technological developments, these HA fillers are manufactured with varying degree of strengths and properties, so as to address a wide range of aesthetic issues. That being said, non-HA implants do have their own advantages, including the ability to promote collagen synthesis in the body via neocollagenesis and a longer residence time. Hence, aestheticians should discuss these treatment realities with their patients and carefully choose the most suitable dermal filler on the basis of a patient’s skin conditions, budget, and desired outcome(s).


[1] Health DO, ‘Review of the Regulation of Cosmetic Interventions’, Springer International Publishing, 2013, https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/192028/Review_of_the_ Regulation_of_Cosmetic_Interventions.pdf

[2] FDA. Dermal Fillers Approced by the Center for Devices and Radiological Health, (2011) https://www.fda.gov/medicaldevices/productsandmedicalprocedures/cosmeticdevices/wrinklefillers/ucm227749.htm

[3] Pierre S, Liew S, Bernardin A. Basics of dermal filler rheology. Dermatol Surg. (2015) Apr;41 Suppl 1:S120–6.

[4] Kablik J, Monheit GD, Yu L, Chang G, Gershkovich J. Comparative physical properties of hyaluronic acid dermal fillers. Dermatologic Surgery. 2009 Feb;35 Suppl 1:302–12.

[5] Erickson M, Stern R, ‘Chain gangs: new aspects of hyaluronan metabolism,’ Biochem Res Int, 2012.

[6] Reed RK, Lilja K, Laurent TC, ‘Hyaluronan in the rat with special reference to the skin’, Acta Physiol Scand, 1988 Nov;134(3):405–11.

[7] Laurent TC, Laurent UB, Fraser JR, ‘Serum hyaluronan as a disease marker’, Ann Med, 1996 Jun;28(3):241–53.

[8] Schiller S, Dorfman A, ‘The metabolism of mucopolysaccharides in animals. IV. The influence of insulin’, J Biol Chem, 1957 Aug;227(2):625–32.

[9] Triggs-Raine B, Natowicz MR. Biology of hyaluronan: Insights from genetic disorders of hyaluronan metabolism. World J Biol Chem. 2015 Aug;6(3):110–20.

[10] Cavallini M, Gazzola R, Metalla M, Vaienti L, The role of hyaluronidase in the treatment of complications from hyaluronic acid dermal fillers. Aesthet Surg J. (2013) Nov;33(8):1167–74.

[11] Meyer K, Rapport MM. Hyaluronidases. Adv Enzymol Relat Subj Biochem. 1952;13:199–236.

[12] Yeom J, Bhang SH, Kim B-S, Seo MS, Hwang EJ, Cho IH, et al. Effect of cross-linking reagents for hyaluronic acid hydrogel dermal fillers on tissue augmentation and regeneration. Bioconjug Chem. (2010) Feb;21(2):240–7.

[13] Edsman K, Nord LI, hrlund K, L rkner H, Kenne AH. Gel Properties of Hyaluronic Acid Dermal Fillers. Dermatologic Surgery. 2012 Jul;38(7pt2):1170–9.

[14] Prasetyo AD, Prager W, Rubin MG, Moretti EA, Nikolis A. Hyaluronic acid fillers with cohesive polydensified matrix for soft-tissue augmentation and rejuvenation: a literature review. Clin Cosmet Investig Dermatol. 2016;9:257–80.

[15] Mansouri Y, Goldenberg G. Update on Hyaluronic Acid Fillers for Facial Rejuvenation. Center for Devices and Radiological Health. Available from: http://www.mdedge.com/cutis/article/101904/aesthetic-dermatology/update-hyaluronic-acid-fillers-facial-rejuvenation

[16] Lemperle G, Romano JJ, Busso M, ‘Soft tissue augmentation with artecoll: 10-year history, indications, techniques, and complications’, Dermatol Surg, 2003 Jun;29(6):573–87.

[17] Ballin AC, Brandt FS, Cazzaniga A, ‘Dermal fillers: an update’, Am J Clin Dermatol, 2015 Aug;16(4):271–83.

[18] Woerle B, Hanke CW, Sattler G. Poly-L-lactic acid: a temporary filler for soft tissue augmentation. J Drugs Dermatol. 2004 Jul;3(4):385–9.

[19] Lisa C. Kates, and Rebecca Fitzgerald, Poly-L-Lactic Acid Injection for HIV-Associated Facial Lipoatrophy: Treatment Principles, Case Studies, and Literature Review (2008)
https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/asj/28/4/10.1016/j.asj.2008.06.005/2/28-4 397.pdf?

[20] Lafaille P, Benedetto A. Fillers: Contraindications, Side Effects and Precautions. J Cutan Aesthet Surg. India: Medknow Publications; 3(1):16–9.

[21] Cohen JL. Understanding, avoiding, and managing dermal filler complications. Dermatol Surg. (2008) Jun;34 Suppl 1:S92–9.

[22] DeLorenzi C, ‘Complications of injectable fillers, part I,’ Aesthet Surg J, 2013 May;33(4):561–75.

[23] Alijotas-Reig J, Fernandez-Figueras MT, Puig L, ‘Inflammatory, immune-mediated adverse reactions related to soft tissue dermal fillers’, Semin Arthritis Rheum, 2013 Oct;43(2):241–58.

[24] DeLorenzi C, ‘Complications of injectable fillers, part 2: vascular complications’, Aesthet Surg J, 2014 May;34(4):584–600.

[25] Kim H-J, Seo K, Lee H-K, Kim J. Clinical Anatomy of the Face for Filler and Botulinum Toxin injection. Cutis. illustrated. (2015) Aug 1;96(2).

Note on articles: These articles are not endorsed by DoctorMedica nor reviewed for medical accuracy. Similarly, views and opinions expressed are those of the author only. Articles are meant for informational purposes only. Ask your doctor for professional medical advice.

Contact us
Mon-Fri 9am to 6pm EST
Email info@doctormedica.co
Phone 1-866-343-2413
Fax 1-888-793-2862